| Literature DB >> 30603026 |
Grzegorz M Kubiak1, Magdalena Dobrolińska2, Elżbieta Pociask3, Wojciech Wańha2, Paweł Gąsior2, Grzegorz Smolka2, Andrzej Ochała2, Wojciech Wojakowski2, Tomasz Roleder4.
Abstract
INTRODUCTION: Coronary artery bypass grafting (CABG) is a method of choice in treatment of diffuse coronary artery disease (CAD), although it has some limitations such as late saphenous vein graft (SVG) patency loss, which occurs in one fifth of all conduits at 5 years. Since atherosclerosis in SVG has diffuse characteristics, it appears that significantly and non-significantly stenosed lesions may have an equal impact on worse prognosis. AIM: To assess non-significant lesions of SVG by the use of optical coherence tomography (OCT) and investigate the clinical and laboratory findings with the potential impact on plaque composition.Entities:
Keywords: coronary artery disease; optical coherence tomography; saphenous vein graft coronary artery bypass grafting
Year: 2018 PMID: 30603026 PMCID: PMC6309833 DOI: 10.5114/aic.2018.79866
Source DB: PubMed Journal: Postepy Kardiol Interwencyjnej ISSN: 1734-9338 Impact factor: 1.426
Figure 1Different types of lesions in saphenous vein grafts – morphology specified in the text: A – fibrotic lesion, B – calcified lesion, C – lipid-rich plaque, D – thin-cap fibroatheroma, E – intimal tearing, F – intimal rupture, G – friable tissue, H – plaque rupture
Patients’ characteristics (n = 29)
| Clinical data | Results |
|---|---|
| Male, | 24 (83) |
| Age, mean ± SD | 69.07 ±7.56 |
| Body mass index, median (IQR) [kg/m2] | 28.5 (26–32) |
| Non-ST elevated myocardial infarction, | 1 (3) |
| Unstable angina, | 10 (35) |
| Stable angina, | 18 (62) |
| Risk factors: | |
| Hypertension, | 26 (90) |
| Current smoking, | 13 (45) |
| Hyperlipidemia, | 25 (86) |
| Diabetes, | 2 (7) |
| Time from CABG, median (IQR) [months] | 143 (100–212) |
| Number of saphenous vein grafts, | |
| 1 | 4 (14) |
| 2 | 18 (62) |
| 3 | 7 (24) |
| Arterial graft (LIMA-LAD), | 26 (90) |
| Pharmacological therapy, | |
| β-Adrenergic antagonist | 25 (86) |
| Calcium channel antagonist | 4 (14) |
| Aspirin | 28 (97) |
| Thienopyridine | 2 (7) |
| Statin | 29 (100) |
| ARB/ACEI | 20 (69) |
| Other lipid-lowering therapy | 6 (21) |
| Insulin | 2 (7) |
| Oral antidiabetics | 5 (17) |
| Laboratory results: | |
| GFR, median (IQR) [ml/min/1.73 m2] | 71 (53–88) |
| White blood cells, median (IQR) [× 103/μl] | 6.32 (5.69–7.24) |
| Platelets, median (IQR) [× 103/μl] | 184 (161–228) |
| Hemoglobin, median (IQR) [mg/dl] | 14.08 (12.90–15.22) |
| Total cholesterol, mean ± SD [mg/dl] | 162.29 ±58.52 |
| LDL cholesterol, median (IQR) [mg/dl] | 78 (68–98) |
| Triglyceride, median (IQR) [mg/dl] | 132 (103–157) |
| HDL cholesterol, median (IQR) [mg/dl] | 41 (32–48) |
SD – standard deviation, IQR – interquartile range, CABG – coronary artery bypass grafting, LIMA-LAD – left internal mammary artery to left anterior descending artery, ARB – angiotensin II receptor blocker, ACEI – angiotensin-converting-enzyme inhibitor, LDL – low-density lipoproteins, HDL – high-density lipoproteins, GFR – glomerular filtration rate.
Optical coherence tomography derived data concerning plaque characteristics
| Optical coherence tomography findings | Non-significantly stenosed lesions ( |
|---|---|
| Region of interest, median (IQR) [mm] | 11.2 (8.0–13.2) |
| Ref. lumen CSA, median (IQR) [mm2] | 7.5 (5.6–8.7) |
| Ref. mean lumen diameter, median (IQR) [mm] | 3.1 (2.7–3.3) |
| Minimal lesion lumen CSA [mm2] | NA |
| Minimal lumen diameter, median (IQR) [mm] | 2.8 (2.5–3.1) |
| Area stenosis, median (IQR) [%] | 15.0 (13.0–17.0) |
| Diameter stenosis, median (IQR) [%] | 0.0 (0.0–5.0) |
| Maximal cap thickness, median (IQR) [μm] | 140.0 (125–155) |
| Maximal lipid arc, median (IQR) [o] | 94.0 (75–120) |
| Maximal calcification arc, median (IQR) [o] | 107.5 (74.0–144.0) |
| Plaque calcification, | 16 (37) |
| TCFA, | 0 (0) |
| Thrombus, | 0 (0) |
| Heterogeneous tissue, | 4 (9) |
| Plaque rupture, | 4 (9) |
| Lipid-rich plaque, | 15 (35) |
| Dissection, | 0 (0) |
| Intimal tearing, | 2 (5) |
| Intimal rupture, | 3 (7) |
| Tissue friability, | 2 (5) |
| Plaque within the SVG valve, | 0 (0) |
CSA – cross sectional area, IQR – interquartile range, NA – not applicable, Ref. – reference, TCFA – thin-cap fibroatheroma, SVG – saphenous vein graft.
Univariable logistic regression analysis of multiple determinants on each plaque morphology
| Parameter | PRT ( | ITR ( | LRP ( |
|---|---|---|---|
| EEM vol. [mm] | 0.91 (0.66–1.24), 0.531 | 0.92 (0.67–1.25), 0.586 | 1.25 (0.92–1.69), 0.153 |
| Lumen vol. [mm] | 0.94 (0.69–1.28), 0.692 | 0.92 (0.68–1.26), 0.617 | 1.23 (0.91–1.67), 0.178 |
| Min. av. lum. diam [mm] | 1.19 (0.87–1.61), 0.276 | 1.12 (0.82–1.53), 0.471 | 1.14 (0.84–1.55), 0.401 |
| Min. lum. area [mm2] | 1.18 (0.87–1.61), 0.289 | 1.11 (0.81–1.51), 0.519 | 1.13 (0.83–1.55), 0.423 |
| Min. lum. diam. [mm] | 1.13 (0.83–1.55), 0.419 | 1.03 (0.75–1.41), 0.857 | 1.22 (0.90–1.66), 0.197 |
| Plaque vol. [mm] | 0.82 (0.61–1.12), 0.209 | 0.91 (0.67–1.24), 0.536 | 1.26 (0.93–1.71), 0.130 |
| Stenosis EEM [%] | 0.93 (0.68–1.27), 0.640 | 0.91 (0.66–1.24), 0.530 | 0.99 (0.72–1.35), 0.928 |
| Stenosis length [mm] | 0.77 (0.57–1.05), 0.096* | 0.85 (0.62–1.16), 0.297 | 1.24 (0.91–1.68), 0.170 |
| Stenosis reference [%] | 0.86 (0.63–1.17), 0.332 | 0.83 (0.61–1.13), 0.240 | 1.23 (0.90–1.67), 0.187 |
| Surf msr. TLP [mm2] | 0.85 (0.62–1.15), 0.284 | 0.89 (0.65–1.21), 0.450 | 1.27 (0.94–1.72), 0.125 |
| Age [years] | 1.31 (0.97–1.79), 0.084* | 1.37 (1.01–1.85), 0.047* | 1.20 (0.88–1.65), 0.250 |
| Body surface area [m2] | 0.79 (0.56–1.13), 0.196 | 1.35 (0.95–1.90), 0.094* | 0.93 (0.65–1.33), 0.676 |
| BMI [kg/m2] | 0.80 (0.56–1.13), 0.201 | 0.93 (0.65–1.33), 0.690 | 1.00 (0.70–1.44), 0.983 |
| LVEF [%] | 0.94 (0.69–1.29), 0.714 | 0.58 (0.45–0.76), < 0.001* | 1.12 (0.82–1.53), 0.457 |
| Troponin [ng/l] | 0.86 (0.60–1.24), 0.415 | 1.42 (1.01–1.99), 0.051* | 1.21 (0.84–1.73), 0.298 |
| HGB [mg/dl] | 0.91 (0.66–1.25), 0.563 | 0.95 (0.69–1.31), 0.773 | 0.94 (0.68–1.29), 0.694 |
| WBC [103/μl] | 1.11 (0.81–1.53), 0.519 | 1.08 (0.78–1.49), 0.632 | 1.04 (0.76–1.43), 0.802 |
| PLT [103/μl] | 1.12 (0.82–1.54), 0.466 | 0.94 (0.68–1.30), 0.712 | 1.59 (1.20–2.11), 0.002* |
| TCH [mg/dl] | 0.93 (0.66–1.30), 0.668 | 0.63 (0.47–0.85), 0.004* | 1.13 (0.81–1.58), 0.473 |
| TG [mg/dl] | 1.18 (0.84–1.65), 0.337 | 0.74 (0.53–1.02), 0.070* | 0.97 (0.69–1.37), 0.858 |
| LDL [mg/dl] | 0.92 (0.66–1.29), 0.621 | 0.84 (0.60–1.17), 0.308 | 1.08 (0.77–1.51), 0.646 |
| HDL [mg/dl] | 1.86 (1.35–2.57), 0.058* | 0.96 (0.68–1.34), 0.801 | 0.98 (0.70–1.37), 0.897 |
| Creatinine [mg/dl] | 1.12 (0.81–1.54), 0.498 | 1.28 (0.93–1.75), 0.127 | 0.86 (0.62–1.18), 0.346 |
| GFR [ml/min/1.73 m2] | 0.94 (0.68–1.30), 0.702 | 0.57 (0.44–0.75), < 0.001* | 1.14 (0.82–1.57), 0.428 |
| Male | 0.95 (0.69–1.30), 0.737 | 0.99 (0.72–1.35), 0.934 | 0.76 (0.56–1.02), 0.072* |
| Diabetes | 0.85 (0.62–1.15), 0.283 | 1.07 (0.78–1.46), 0.683 | 1.03 (0.76–1.41), 0.840 |
| Hypertension | 1.14 (0.83–1.55), 0.410 | 1.16 (0.85–1.58), 0.350 | 1.34 (1.00–1.81), 0.055* |
| Current smoking | 0.90 (0.66–1.23), 0.513 | 1.14 (0.84–1.56), 0.393 | 1.55 (1.17–2.05), 0.003* |
PRT – plaque rupture, ITR – intimal tearing or rupture, LRP – lipid-rich plaque, EEM – external elastic membrane, TLP – total lumen perimeter, BMI – body mass index, LVEF – left ventricular ejection fraction, HGB – hemoglobin, WBC – white blood cells, PLT – platelets, TCH – total cholesterol, TG – triglycerides, LDL – low-density lipoproteins, HDL – high-density lipoproteins, GFR – glomerular filtration rate.
Univariable logistic regression analysis of multiple determinants on each plaque morphology
| Paramter | FIB ( | CAL ( | FRB ( |
|---|---|---|---|
| EEM vol. [mm] | 1.01 (0.74–1.38), 0.960 | 0.93 (0.68–1.27), 0.655 | 0.83 (0.61–1.13), 0.225 |
| Lumen vol. [mm] | 0.98 (0.72–1.34), 0.885 | 0.96 (0.70–1.31), 0.800 | 0.84 (0.62–1.15), 0.275 |
| Min. av. lum. diam [mm] | 0.91 (0.67–1.25), 0.558 | 1.23 (0.91–1.67), 0.181 | 0.95 (0.69–1.30), 0.738 |
| Min. lum. area [mm2] | 0.94 (0.69–1.28), 0.673 | 1.19 (0.87–1.61), 0.274 | 0.95 (0.69–1.29), 0.733 |
| Min. lum. diam. [mm] | 0.89 (0.65–1.21), 0.448 | 1.18 (0.86–1.60), 0.299 | 0.94 (0.69–1.28), 0.689 |
| Plaque vol. [mm] | 1.10 (0.81–1.51), 0.529 | 0.86 (0.63–1.17), 0.328 | 0.80 (0.59–1.08), 0.150 |
| Stenosis EEM [%] | 1.19 (0.88–1.62), 0.257 | 0.86 (0.63–1.16), 0.316 | 0.87 (0.64–1.18), 0.359 |
| Stenosis length [mm] | 1.05 (0.77–1.43), 0.759 | 0.81 (0.60–1.10), 0.176 | 0.84 (0.62–1.14), 0.263 |
| Stenosis reference [%] | 0.98 (0.72–1.34), 0.898 | 0.79 (0.58–1.07), 0.134 | 0.98 (0.72–1.34), 0.883 |
| Surf msr. TLP [mm2] | 1.02 (0.75–1.39), 0.897 | 0.90 (0.66–1.22), 0.484 | 0.82 (0.61–1.12), 0.211 |
| Age [years] | 0.93 (0.68–1.28), 0.648 | 1.28 (0.94–1.74), 0.122 | 1.16 (0.85–1.59), 0.352 |
| Body surface area [m2] | 1.53 (1.11–2.12), 0.014* | 0.95 (0.66–1.36), 0.764 | 0.81 (0.57–1.16), 0.248 |
| BMI [kg/m2] | 1.28 (0.91–1.82), 0.161 | 0.77 (0.54–1.08), 0.133 | 0.89 (0.62–1.27), 0.520 |
| LVEF [%] | 0.85 (0.62–1.16), 0.300 | 0.91 (0.66–1.24), 0.534 | 1.05 (0.77–1.43), 0.755 |
| Troponin [ng/l] | 0.80 (0.56–1.15), 0.230 | 1.13 (0.78–1.62), 0.512 | 1.36 (0.96–1.93), 0.083* |
| HGB [mg/dl] | 1.06 (0.77–1.46), 0.708 | 0.81 (0.59–1.11), 0.184 | 0.91 (0.66–1.26), 0.575 |
| WBC [103/μl] | 0.94 (0.68–1.29), 0.697 | 1.35 (0.99–1.83), 0.057* | 0.96 (0.70–1.32), 0.795 |
| PLT [103/μl] | 0.75 (0.55–1.02), 0.067* | 0.95 (0.69–1.30), 0.739 | 0.94 (0.68–1.30), 0.704 |
| TCH [mg/dl] | 0.78 (0.56–1.09), 0.147 | 0.71 (0.52–0.98), 0.040* | 1.08 (0.77–1.52), 0.634 |
| TG [mg/dl] | 0.66 (0.48–0.91), 0.013* | 1.01 (0.72–1.43), 0.939 | 1.15 (0.82–1.61), 0.423 |
| LDL [mg/dl] | 0.80 (0.58–1.12), 0.195 | 0.87 (0.63–1.22), 0.428 | 1.04 (0.74–1.45), 0.833 |
| HDL [mg/dl] | 1.35 (0.98–1.86), 0.072* | 0.68 (0.49–0.92), 0.016* | 1.00 (0.71–1.40), 0.980 |
| Creatinine [mg/dl] | 1.21 (0.88–1.67), 0.230 | 1.02 (0.74–1.41), 0.911 | 0.85 (0.62–1.17), 0.315 |
| GFR [ml/min/1.73 m2] | 0.90 (0.65–1.24), 0.510 | 0.83 (0.61–1.15), 0.260 | 1.00 (0.72–1.38), 0.996 |
| Male | 1.64 (1.25–2.16), 0.001* | 1.00 (0.73–1.36), 0.985 | 0.63 (0.48–0.83), 0.002* |
| Diabetes | 0.84 (0.62–1.14), 0.263 | 1.08 (0.79–1.48), 0.618 | 1.24 (0.91–1.68), 0.165 |
| Hypertension | 0.73 (0.55–0.99), 0.043* | 1.36 (1.01–1.83), 0.043* | 1.09 (0.80–1.49), 0.571 |
| Current smoking | 0.66 (0.50–0.88), 0.006* | 0.92 (0.68–1.26), 0.606 | 1.36 (1.01–1.83), 0.043* |
FIB – fibrotic plaque, CAL – calcified plaque, FRB – friable tissue, other abbreviations as in Table III.
Figure 2Logistic regression primary models of OCT-based prediction for different plaque types
HDL – high-density lipoproteins, GFR – glomerular filtration rate, LVEF – left ventricular ejection fraction.
Figure 3Logistic regression secondary models of OCT-based prediction for different plaque types
HDL – high-density lipoproteins, GFR – glomerular filtration rate.